Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses
about
Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challengeIntranasal vaccination with murabutide enhances humoral and mucosal immune responses to a virus-like particle vaccineNasal vaccine innovation.Vaccine against norovirus.Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculationA human norovirus-like particle vaccine adjuvanted with ISCOM or mLT induces cytokine and antibody responses and protection to the homologous GII.4 human norovirus in a gnotobiotic pig disease model.Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice.Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo.Structural requirements for the assembly of Norwalk virus-like particlesSystemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles.Mucosal immunity and vaccines.An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles.Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: a new vaccine candidate against an important noncultivable virus.Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine.Noroviruses: The leading cause of gastroenteritis worldwideImmunogenicity of HIV virus-like particles in rhesus macaques by intranasal administration.Immunogenicity of Newcastle disease virus vectors expressing Norwalk virus capsid protein in the presence or absence of VP2 protein.Advances in mucosal vaccination.Low-affinity B cells transport viral particles from the lung to the spleen to initiate antibody responsesNorovirus capture with histo-blood group antigens reveals novel virus-ligand interactions.Antibody is critical for the clearance of murine norovirus infection.Rotavirus enterotoxin NSP4 has mucosal adjuvant properties.Pattern of activation of human antigen presenting cells by genotype GII.4 norovirus virus-like particlesAdjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissuesGenogroup II noroviruses efficiently bind to heparan sulfate proteoglycan associated with the cellular membrane.Targeting mucosal dendritic cells with microbial antigens from probiotic lactic acid bacteria.Norovirus vaccine against experimental human Norwalk Virus illness.An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles.Listeria monocytogenes delivery of HPV-16 major capsid protein L1 induces systemic and mucosal cell-mediated CD4+ and CD8+ T-cell responses after oral immunizationBiological gene delivery vehicles: beyond viral vectors.Virus-like particle vaccines and adjuvants: the HPV paradigm.Comparative evaluation of recombinant protein production in different biofactories: the green perspective.Norwalk virus-like particles as vaccines.Heat shock protein 70 enhances mucosal immunity against human norovirus when coexpressed from a vesicular stomatitis virus vector.Developments in virus-like particle-based vaccines for infectious diseases and cancer.Norovirus virus-like particle vaccines for the prevention of acute gastroenteritis.Progress towards the prevention and treatment of norovirus infections.Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies.Nasal and pulmonary vaccine delivery using particulate carriers.Different applications of virus-like particles in biology and medicine: Vaccination and delivery systems.
P2860
Q24657762-2134ADCA-AE40-4328-98D5-FD1503950EF9Q28728786-1676C1F1-EBD9-4999-A009-C6306BFAE55DQ30395810-0FA371D6-5E3B-4913-9BCF-66B2D7BA5CC4Q33578075-387979B8-6D33-4BC4-AB34-8D8936F56A19Q33788701-8EE70F7A-22A2-45C6-9DC4-EC7F873E4260Q33889379-A0973426-D5CB-41A3-8D96-3B7A8B113C2EQ33962224-8778F5F3-39E5-4EFD-9577-F28AEBA8CB3DQ34291161-AA27B680-CA2D-48FF-AEAF-46536249A863Q34335587-38ECACE2-A710-412C-9BDB-79548BCFB03FQ34357038-E55FCCA3-BD5A-4598-AD12-32B9FDEEA957Q34409172-473E457F-02BD-4439-9347-1B4D80CD6E65Q34431983-A479C9C1-E274-4466-B587-B7FC459312A3Q34742846-122C2B6D-CE57-47E4-A980-93A6D889F0FCQ35112676-C7F2E456-6987-4536-B9CE-8E8C5AAE0C97Q35148970-1C966FE6-66DE-4D95-9B88-0B7E4266FC05Q36017750-AB111D9D-5E2B-4A11-B805-1DCB3E54E3A1Q36052875-9172D2B4-EFF9-4E9D-9432-B7177DBB262EQ36177348-3B8B242C-503F-4277-A20D-849FAD9C3F7FQ36483586-4F628E1C-16F7-4881-8EE0-D5BC9C927A7EQ36510326-727FE42D-3F23-4E92-B5FE-990BF79C3783Q36747984-E0B092B1-E5D1-4610-945D-96C6A77086D3Q36873521-4060CAED-4D22-4CA3-9D82-9A24552F8D41Q36898311-B0415E3C-9480-4A65-9A6B-EB6068BF473CQ37044185-F6E32BA1-7585-4490-B345-F3060EADE0BCQ37093113-EBBEFA96-8B1C-41EF-9B7D-CAD01815A3D2Q37103921-31868BF4-7565-44A3-A86C-2B729BB950A9Q37144052-363EEA09-3775-48FB-9991-97950A400EE1Q37348115-AD3D6C5E-9C56-47C9-AE87-786AA3D7DA29Q37391175-81ED1461-C280-4BB4-8F0C-666CEA286186Q37412239-B070D0D8-275C-421E-AA3E-27042C0344C0Q37608311-761D4179-1C5B-48E8-9512-7FC517699F7DQ37679720-31ACB8E5-21BF-4B22-B6AE-EAD949EB6DD1Q37706587-6FD50003-486A-4E0F-9CFA-BBAAC89992C5Q37713979-660E8F4A-0B03-4E06-950C-E77902C26E04Q37951525-12A3D46B-A35A-4537-9BDB-3CB648BB5A44Q38081967-88319F59-12F7-44B0-9A5E-D8FE9FD96E16Q38160537-B5E0C83F-D7F0-4362-B543-26BF73DDC173Q38461061-554A84A1-A34D-4053-B4F0-8436AEB7A814Q38465267-53120BED-DA8D-4140-969B-F9C369E273CBQ38618258-D186EC9F-7968-4542-896E-0D164822E6EE
P2860
Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Recombinant Norwalk virus-like ...... and vaginal) immune responses
@ast
Recombinant Norwalk virus-like ...... and vaginal) immune responses
@en
type
label
Recombinant Norwalk virus-like ...... and vaginal) immune responses
@ast
Recombinant Norwalk virus-like ...... and vaginal) immune responses
@en
prefLabel
Recombinant Norwalk virus-like ...... and vaginal) immune responses
@ast
Recombinant Norwalk virus-like ...... and vaginal) immune responses
@en
P2093
P2860
P1433
P1476
Recombinant Norwalk virus-like ...... and vaginal) immune responses
@en
P2093
J D Clements
R A Guerrero
S E Pacheco
S S Krater
P2860
P304
P356
10.1128/JVI.75.20.9713-9722.2001
P577
2001-10-01T00:00:00Z